Avelumab or talazoparib in combination with binimetinib in metastatic pancreatic ductal adenocarcinoma: dose-finding results from phase Ib of the JAVELIN PARP MEKi trial

J. Rodon Ahnert, D. S.W. Tan, I. Garrido-Laguna, W. Harb, A. Bessudo, J. T. Beck, S. Rottey, N. Bahary, N. Kotecki, Z. Zhu, S. Deng, K. Kowalski, C. Wei, N. Pathan, R. J. Laliberte, W. A. Messersmith

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Fingerprint

Dive into the research topics of 'Avelumab or talazoparib in combination with binimetinib in metastatic pancreatic ductal adenocarcinoma: dose-finding results from phase Ib of the JAVELIN PARP MEKi trial'. Together they form a unique fingerprint.

Medicine & Life Sciences